[1] Rosas H H, Cuevas E, Raymick J B, et al. Characterization of serum exosomes from a transgenic mouse model of alzheimer's disease[J]. Curr Alzheimer Res, 2019, 16(5): 388-395.
[2] Terada T, Therriault J, Kang M S P,et al. Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease.[J].Mol Neurodegener, 2021, 16(1): 28.
[3] King A, Szekely B,Calapkulu E, et al. The increased densities, but different distributions, of both C3 and S100A10 immunopositive astrocyte-like cells in alzheimer's disease brains suggest possible roles for both A1 and A2 astrocytes in the disease pathogenesis[J]. Brain Sci, 2020, 10(8): 503.
[4] Goetzl E J, Schwartz J B, Abner E L, et al. High complement levels in astrocyte-derived exosomes of Alzheimer disease[J]. Ann Neurol, 2018, 83(3): 544-552.
[5] Nogueras-Ortiz C J, Mahairaki V, Delgado-Peraza F. Astrocyte-and neuron-derived extracellular vesicles from alzheimer's disease patients effect complement-mediated neurotoxicity[J]. 2020, 9(7): 1618.
[6] Ribaudo G,Coghi P, Zanforlin E, et al. Semi-synthetic isoflavones as bace-1 inhibitors against alzheimer's disease[J].Bioorg Chem, 2019, 87(6): 474-483.
[7] Pascua-Maestro R, González E, Lillo C, et al. Extracellular vesicles secreted by astroglial cells transport apolipoprotein d to neurons and mediate neuronal survival upon oxidative stress[J]. Front Cell Neurosci, 2018, 12(1): 526.
[8] Pei X, Li Y, Zhu L, et al. Astrocyte-derived exosomes suppress autophagy and ameliorate neuronal damage in experimental ischemic stroke[J]. Exp Cell Res, 2019, 382(2): 111474.
[9] Pei X, Li Y, Zhu L, et al. Astrocyte-derived exosomes transfer miR-190b to inhibit oxygen and glucose deprivation-induced autophagy and neuronal apoptosis[J]. Cell Cycle, 2020, 19(8): 906-917.
[10] Guitart K, Loers G, Buck F, et al. Improvement of neuronal cell survival by astrocyte-derived exosomes under hypoxic and ischemic conditions depends on prion protein[J]. Glia, 2016, 64(6): 896-910.
[11] Xu L, Cao H, Xie Y, et al. Exosome-shuttled miR-92b-3p from ischemic preconditioned astrocytes protects neurons against oxygen and glucose deprivation[J]. Brain Res, 2019, 1717(5): 66-73.
[12] Bu X, Li D, Wang F, et al. Protective role of astrocyte-derived exosomal microRNA-361 in cerebral ischemic-reperfusion injury by regulating the AMPK/mTOR signaling pathway and targeting CTSB[J]. Neuropsychiatr Dis Treat, 2020, 16(6): 1863-1877.
[13] Song H, Zhang X, Chen R, et al. Cortical Neuron-derived exosomal microRNA-181c-3p inhibits neuroinflammation by downregulating CXCL1 in astrocytes of a rat model with ischemic brain injury[J]. Neuroimmunomodulation, 2019, 26(5): 217-233.
[14] Huang B, Jiang X C, Zhang T Y, et al. Peptide modified mesenchymal stem cells as targeting delivery system transfected with miR-133b for the treatment of cerebral ischemia[J].Int J Pharm, 2017, 531(1): 90-100.
[15] Hira K, Ueno Y, Tanaka R, et al. Astrocyte-derived exosomes treated with a semaphorin 3A inhibitor enhance stroke recovery via prostaglandin D(2) synthase[J]. Stroke, 2018, 49(10): 2483-2494.
[16] Wu W, Liu J, Yang C, et al. Astrocyte-derived exosome-transported microRNA-34c is neuroprotective against cerebral ischemia/reperfusion injury via TLR7 and the NF-κB/MAPK pathways[J]. Brain Res Bull, 2020, 163(10): 84-94.
[17] Silverman J M, Christy D, Shyu C C, et al. CNS-derived extracellular vesicles from superoxide dismutase 1 (SOD1)(G93A) ALS mice originate from astrocytes and neurons and carry misfolded SOD1[J]. 2019, 294(10): 3744-3759.
[18] Basso M, Pozzi S, Tortarolo M, et al. Mutant copper-zinc superoxide dismutase (SOD1) induces protein secretion pathway alterations and exosome release in astrocytes: implications for disease spreading and motor neuron pathology in amyotrophic lateral sclerosis[J]. J Biol Chem, 2013, 288(22): 15699-15711.
[19] Morel L, Regan M, Higashimori H, et al. Neuronal exosomal miRNA-dependent translational regulation of astroglial glutamate transporter GLT1[J]. J Biol Chem, 2013, 288(10): 7105-7116.
[20] Chen Y, Xia K, Chen L, et al. Increased interleukin-6 levels in the astrocyte-derived exosomes of sporadic amyotrophic lateral sclerosis patients[J]. Front Neurosci, 2019, 13(6): 574.
[21] Stefanis L, Emmanouilidou E, Pantazopoulou M, et al. How is alpha-synuclein cleared from the cell?[J]. J Neurochem, 2019, 150(5): 577-590.
[22] Sorrentino Z A, Giasson B I, Chakrabarty P. α-synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in lewy body disease[J]. Acta Neuropathol, 2019, 138(1): 1-21.
[23] Ishii T, Warabi E, Mann G E. Circadian control of BDNF-mediated Nrf2 activation in astrocytes protects dopaminergic neurons from ferroptosis[J]. Free Radic Biol Med, 2019, 133(3): 169-178.
[24] Ohmichi T, Mitsuhashi M, Tatebe H, et al. Quantification of brain-derived extracellular vesicles in plasma as a biomarker to diagnose Parkinson's and related diseases[J]. Parkinsonism Relat Disord, 2019, 61(4): 82-87.